Elhannan Sahar, Taha Safa, Ben Khalaf Noureddine, Bakheit Halla, Fathallah M Dahmani, Bakhiet Moiz
Department of Molecular Medicine, Princess Al‑Jawhara Center for Genetics and Inherited Diseases, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain.
Biotechnology Program, College of Graduate Studies, Arabian Gulf University, Manama, Bahrain.
Int J Mol Med. 2015 Dec;36(6):1583-92. doi: 10.3892/ijmm.2015.2376. Epub 2015 Oct 15.
The immune system-released activating agent (ISRAA) is an immune mediator activated as a result of a nerve stimulus initiated by immune challenge. We have previously demonstrated that ISRAA and tumor necrosis factor (TNF) receptor 1 (TNFR1) share an interspecies-conserved motif (72% homology) that induces the apoptosis and proliferation of human peripheral blood mononuclear cells (hPBMCs) in a dose-dependent manner. In the present study, cytokine profiles were examined in response to the stimulation of hPBMCs with ISRAA. Furthermore, the signaling pathways induced by ISRAA were mapped. The results revealed high measurable levels of TNF-α, interleukin (IL)-6, IL-8, IL-10 and interferon (IFN)-γ, but not IL-4, IL-17 (IL-17A) or transforming growth factor (TGF)-β. The analysis of signaling pathways revealed the activation of extracellular-regulated protein kinase (ERK)1/2 as a downstream signal in the mitogen‑activated protein kinase (MAPK) pathway during TNF‑α and IL-6 production and apoptosis, but not during proliferation following stimulation with ISRAA by triggering the Fas-associated protein with death domain (FADD). STAT3 was found to be unphosphorylated in the ISRAA‑stimulated hPBMCs, and STAT3 was ubiquitously expressed in unstimulated cells, suggesting that ISRAA has a protein inhibitor of activated STAT (PIAS)-like activity, by functioning as a negative regulator of the effects of STAT3 on the Janus kinase (JAK)/STAT pathway. The determination of the nature of cytokine responses together with the signaling pathways of cellular activity induced by ISRAA paves the way for the investigation of a potential target of ISRAA and for the development of novel therapeutic approaches for the treatment of immune-regulated disorders.
免疫系统释放的激活剂(ISRAA)是一种免疫介质,因免疫挑战引发的神经刺激而被激活。我们之前已经证明,ISRAA与肿瘤坏死因子(TNF)受体1(TNFR1)共享一个种间保守基序(72%同源性),该基序以剂量依赖的方式诱导人外周血单核细胞(hPBMCs)的凋亡和增殖。在本研究中,检测了hPBMCs在ISRAA刺激下的细胞因子谱。此外,还绘制了ISRAA诱导的信号通路。结果显示,TNF-α、白细胞介素(IL)-6、IL-8、IL-10和干扰素(IFN)-γ的水平可检测到较高,但IL-4、IL-17(IL-17A)或转化生长因子(TGF)-β则未检测到。信号通路分析显示,在TNF-α和IL-6产生及凋亡过程中,细胞外调节蛋白激酶(ERK)1/2作为丝裂原活化蛋白激酶(MAPK)通路的下游信号被激活,但在用ISRAA刺激后增殖过程中未被激活,这是通过触发死亡结构域相关蛋白(FADD)实现的。在ISRAA刺激的hPBMCs中,STAT3未被磷酸化,且STAT3在未刺激的细胞中普遍表达,这表明ISRAA具有类似活化STAT蛋白抑制剂(PIAS)的活性,通过作为STAT3对Janus激酶(JAK)/STAT通路作用的负调节因子发挥作用。确定细胞因子反应的性质以及ISRAA诱导的细胞活性信号通路,为研究ISRAA的潜在靶点以及开发治疗免疫调节紊乱的新型治疗方法铺平了道路。